NASDAQ · Biotechnology

Iterum Therapeutics plc (ITRM) Stock

$0.03 -10.98% NASDAQ: ITRM Healthcare

Iterum Therapeutics plc is a clinical-stage biopharmaceutical firm dedicated to the development and commercialization of anti-infective treatments. The company operates across Ireland, Bermuda, and the United States.

Valuation

MetricValue
Price$0.03
Market Cap$1.60M
P/E Ratio-0.06
P/B Ratio-0.19
P/S Ratio4.10
EPS (TTM)$-1.26
52-Week High$1.42
52-Week Low$0.03
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE442.32%
ROA-62.70%
ROCE-63.75%
Gross Margin-171.28%
Operating Margin—
Net Margin—
Debt/Equity-4.57
Current Ratio2.13

Annual Financials (USD)

Metric20202021202220232024
Revenue$0$0$0$0$0
Operating Profit$-32.0M$-25.0M$-30.0M$-47.0M$-19.0M
Net Profit$-52.0M$-92.0M$-44.0M$-38.0M$-25.0M
EPS$-32.49$-8.41$-3.63$-2.96$-1.26
Op Margin—————

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$33.0M$92.0M$67.0M$26.0M$45.0M
Total Liabilities$83.0M$41.0M$39.0M$33.0M$49.0M
Cash$15.0M$27.0M$21.0M$6.0M$24.0M
Borrowings$48.0M$30.0M$30.0M$19.0M$46.0M

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-55.0M$-16.0M$-18.0M$-39.0M$-27.0M
Investing Cash Flow$0$-55.0M$14.0M$23.0M$18.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$10.0M$13.0M$-6.0M$-15.0M$18.0M
Free Cash Flow$-55.0M$-16.0M$-19.0M$-39.0M$-27.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-1.38
FCF Yield-980.34%
Quick Ratio1.96
Interest Coverage-11.67
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANTX $4.93 +0.20% -4.76 $177.56M 0.00%
BOLD $2.48 -3.50% -0.56 $55.74M 0.00%
IBIO $1.45 +1.40% -0.91 $22.89M 0.00%
INTS $4.57 +2.70% -0.60 $12.35M 0.00%
KLTOKlotho Neurosciences, Inc. $0.38 -7.10% -1.13 $20.08M 0.00%

About Iterum Therapeutics plc

Iterum Therapeutics plc is a clinical-stage biopharmaceutical firm dedicated to the development and commercialization of anti-infective treatments. The company operates across Ireland, Bermuda, and the United States. Its primary therapeutic candidate is sulopenem, an innovative antimicrobial compound available in both oral and intravenous formulations. Sulopenem is currently undergoing advanced (Phase III) clinical evaluation for its potential in addressing uncomplicated and complicated urinary tract infections, as well as complicated intra-abdominal infections. Established in 2015, Iterum Therapeutics maintains its corporate headquarters in Dublin, Ireland.

Iterum Therapeutics plc is headquartered in IE.

Iterum Therapeutics plc (ITRM) stock trades at $0.03 with a market capitalization of $1.60M. The stock is valued at a price-to-earnings (P/E) ratio of -0.06, price-to-book of -0.19, price-to-sales of 4.10. Over the past 52 weeks the stock has ranged between $0.03 and $1.42, and currently trades 97.9% below its 52-week high.

On profitability, Iterum Therapeutics plc generates a return on equity (ROE) of 442.32% — well above the market average, a sign of a high-quality business, return on capital employed of -63.75%.

Official website: www.iterumtx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides